In male mice that are food-restricted, a single injection of semaglutide reduces behaviors related to seeking sugary rewards while increasing activity in dopamine-producing brain cells during...
Mechanism
Synthesis from 1 study
The drug tells the mouse’s brain it’s full, so it stops trying so hard to get sugar. But when the mouse finally eats it, the brain’s pleasure center gets extra active — not because it’s hungrier, but because the drug is directly turning up the signal during eating. These two effects happen through...
Most probable mechanism
The drug makes the mice less motivated to work for sugar, but when they finally eat it, their brain's reward center becomes more active. This happens because the drug first tells the brain it's full, so the mice stop trying hard to get the treat, but separately, it also turns up the signal in the brain's pleasure center during the actual eating, without changing how the brain responds to the cue that sugar is coming.
Semaglutide activates GLP-1 receptors in the nucleus tractus solitarius and arcuate nucleus, suppressing hunger signals and reducing motivation to seek food
Semaglutide indirectly activates neural projections from the nucleus tractus solitarius, arcuate nucleus, or lateral septum to the ventral tegmental area
These projections selectively increase excitatory drive to dopamine neurons in the ventral tegmental area specifically during reward consumption, not during predictive cues
The increase in dopamine neuron activity during consumption occurs independently of changes in reward-seeking behavior, indicating dissociation between motivational and consummatory pathways
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.